Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	5.14	4.62	0
Cash & Short-Term Investments	5.14	4.62	0
Cash Growth	11.30%	230950.00%	-
Prepaid Expenses	-	0.38	2.31
Other Current Assets	0.03	-	-
Total Current Assets	5.17	5	2.32
Total Assets	5.17	5	2.32
Accounts Payable	0.47	0.07	0.47
Accrued Expenses	0.14	0.22	0.44
Short-Term Debt	-	-	0.13
Total Current Liabilities	0.61	0.29	1.04
Total Liabilities	0.61	0.29	1.04
Common Stock	0.01	0	0
Additional Paid-In Capital	104.2	95.36	61.57
Retained Earnings	-99.64	-90.65	-60.29
Shareholders' Equity	4.57	4.71	1.28
Total Liabilities & Equity	5.17	5	2.32
Total Debt	-	-	0.13
Net Cash (Debt)	5.14	4.62	-0.13
Net Cash Growth	11.30%	-	-
Net Cash Per Share	0.11	0.14	-0.01
Filing Date Shares Outstanding	47.34	41.15	10.69
Total Common Shares Outstanding	47.34	41.15	10.69
Working Capital	4.57	4.71	1.28
Book Value Per Share	0.10	0.11	0.12
Tangible Book Value	4.57	4.71	1.28
Tangible Book Value Per Share	0.10	0.11	0.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q